 Infection with human papillomavirus HPV has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years after administration of the first dose of HPV vaccine Month 0 administered in the primary study 580299013. This protocol posting deals with objectives outcome measures of the extension phase from Month 60 to Month 120. The objectives outcome measures of the primary phase are presented in a separate protocol posting NCT00196924. The objectives outcome measures of the extension phase up to Month 48 are presented in a separate protocol posting NCT00316706. 